Abstract:Bone morphogenetic proteins (BMPs) have been widely investigated for treating non-healing fractures. They participate in bone reconstruction by inducing osteoblast differentiation, and osteoid matrix production. 1 The human recombinant protein of BMP-7 was among the first growth factors approved for clinical use. Despite achieving comparable results to autologous bone grafting, severe side effects have been associated with its use. 2 Furthermore, BMP-7 was removed from the market. 3 These complications are related to the high doses used (1.5-40 miligrams per surgery) 2 compared to the physiological concentration of BMP in fracture healing (in the nanogram to picogram per milliliter range). 4 In this study, we use transcript therapy to deliver chemically modified mRNA (cmRNA) encoding BMP-7. Compared to direct use of proteins, transcript therapy allows the sustained synthesis of proteins with native conformation and true post-translational modifications using doses comparable to the physiological ones. 5 Moreover, cmRNA technology overcomes the safety and affordability limitations of standard gene therapy i.e. pDNA. 6 BMP-7 cmRNA was delivered using LipofectamineTM MessengerMAXTM to human mesenchymal stromal cells (hMSCs). We assessed protein expression and osteogenic capacity of hMSCs in monolayer culture and in a house-made, collagen hydroxyapatite scaffold. Using fluorescently-labelled cmRNA we observed an even distribution after loading complexes into the scaffold and a complete release after 3 days. For both monolayer and 3D culture, BMP-7 production peaked at 24 hours post-transfection, however cells transfected in scaffolds showed a sustained expression. BMP-7 transfected hMSCs yielded significantly higher ALP activity and Alizarin red staining at later timepoints compared to the untransfected group. Interestingly, BMP-7 cmRNA treatment triggered expression of osteogenic genes like OSX, RUNX-2 and OPN, which was also reflected in immunostainings. This work highlights the relevance of cmRNA technology that may overcome the shortcomings of protein delivery while circumventing issues of traditional pDNA-based gene therapy for bone regeneration. Acknowledgement: This work has been performed as part of the cmRNAbone project and has received funding from the European Union's Horizon 2020 research and innovation programme under the Grant Agreement No 874790.

[A novel human bone morphogenetic protein-7 variant with an enriched heparin-binding site]

Studies on Recombinant Human Bone Morphogenetic Protein 2 Loaded Nano-Hydroxyapatite/Silk Fibroin Scaffolds

Expression, Purification, and Refolding of a Recombinant Human Bone Morphogenetic Protein 2 in Vitro

Heparin-mediated delivery of bone morphogenetic protein-2 improves spatial localization of bone regeneration

BMP2-mimicking Peptide Modified with E7 Coupling to Calcined Bovine Bone Enhanced Bone Regeneration Associating with Activation of the Runx2/SP7 Signaling Axis.

Refolding and two-step purification by hydrophobic interaction chromatography of recombinant human bone morphogenetic protein-2 from Escherichia coli

Expression, purification, and renaturation of bone morphogenetic protein-2 from Escherichia coli

A Process for the Design and Development of Novel Bone Morphogenetic Protein-7 (BMP-7) Mimetics With an Example: THR-184

Novel Synthesized Nanofibrous Scaffold Efficiently Delivered hBMP-2 Encoded in Adenoviral Vector to Promote Bone Regeneration

Fabricating a novel HLC-hBMP2 fusion protein for the treatment of bone defects

The use of heparin/polycation coacervate sustain release system to compare the bone regenerative potentials of 5 BMPs using a critical sized calvarial bone defect model

An activin A/BMP2 chimera, AB204, displays bone-healing properties superior to those of BMP2

Affinity-selected polysaccharide for rhBMP-2-induced osteogenesis via BMP receptor activation

Recombinant Human Bone Morphogenetic Protein 6 Delivered Within Autologous Blood Coagulum Restores Critical Size Segmental Defects of Ulna in Rabbits

TRANSFECTION OF HMSCS WITH CHEMICALLY MODIFIED MRNA CODING FOR BMP-7 ENHANCES OSTEOGENESIS

Collagen-binding bone morphogenetic protein-2 designed for use in bone tissue engineering

A novel BMP-2–loaded hydroxyapatite/beta-tricalcium phosphate microsphere/hydrogel composite for bone regeneration

Identification of a Key Residue Mediating Bone Morphogenetic Protein (BMP)-6 Resistance to Noggin Inhibition Allows for Engineered BMPs with Superior Agonist Activity

Precisely Localized Bone Regeneration Mediated by Marine-Derived Microdroplets with Superior BMP-2 Binding Affinity.

rhBMP2/7 heterodimer: an osteoblastogenesis inducer of not higher potency but lower effective concentration compared with rhBMP2 and rhBMP7 homodimers.

High Molecular Weight Poly(glutamic acid) to Improve BMP2-Induced Osteogenic Differentiation